On January 15, 2019 Reven completed their single-ascending-dose (SAD)/
multiple-ascending-dose (MAD) Phase 1 Clinical Trial in the United States.
Reven is now in the planning stage of their Phase 2 Clinical Trial that will
be conducted in the United States in Q2 of 2019.